Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jose Maria Fernandez Sousa-Faro Ph.D. | Founder, Executive Chairman, CEO & President | 294k | -- | -- |
| Mr. Pedro Francisco Fernandez Puentes | Executive Vice-Chairman | 124k | -- | -- |
| Mr. Juan Carlos-Torres Carretero | Founder | -- | -- | 1949 |
| Ms. María Luisa de Francia Caballero | Chief Financial Officer | -- | -- | -- |
| Mr. José Luis Moreno Martinez-Losa | Head of Capital Markets & Investor Relations | -- | -- | -- |
| Mr. Juan Gomez Pulido | General Counsel & Secretary of the Board of Directors | -- | -- | -- |
| Ms. Sandra Llamera Sanchez | Global Compliance Head | -- | -- | -- |
| Ms. Lara Vadillo | Communication Director | -- | -- | -- |
| Ms. Belén Sopesén Veramendi Ph.D. | Director of Corporate Development | -- | -- | -- |
| Mr. Luis Rupérez Cuenca | Director of Human Resources & IT | -- | -- | -- |
Pharma Mar, S.A.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 509
Description
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Corporate Governance
Upcoming Events
February 26, 2025 at 10:59 AM UTC - March 3, 2025 at 12:00 PM UTC
Pharma Mar, S.A. Earnings Date
Recent Events
June 12, 2024 at 12:00 AM UTC
Ex-Dividend Date